Blue Cell Therapeutics ApS: Financial statements 2020
CVR: 39981610
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Blue Cell Therapeutics ApS (CVR 39981610) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -2,943,601 and a net result of DKK -14,026,899. Equity in the 2020 report amounted to DKK 9,775,822. The solvency ratio was 72.4%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -2,943,601
- Profit/Loss
- DKK -14,026,899
- Equity
- DKK 9,775,822
- Total Assets
- DKK 13,504,095
- Employees
- 2
Official annual report
How creditworthy is Blue Cell Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Blue Cell Therapeutics ApS has published its interim report for the period October 28, 2018 to December 31, 2019.
As of March 30, 2020, Michael Ulveman has joined the board of directors of Blue Cell Therapeutics ApS.
As of March 30, 2020, André Rafal Rogaczewski has joined the board of directors of Blue Cell Therapeutics ApS.
As of March 30, 2020, Thomas Tofte Hansen has left the board of directors of Blue Cell Therapeutics ApS.
As of March 30, 2020, Leif Helth Jensen has left the board of directors of Blue Cell Therapeutics ApS.
On March 30, 2020, the company changed its name from Regenerative Therapeutics IVS to Blue Cell Therapeutics ApS.
About Blue Cell Therapeutics ApS
Blue Cell Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Regenerative Therapeutics IVS. The management consists of Søren Paludan Sheikh. The board consists of Olav Hellebø (chair), Anella Rogaczewski, Michael Ulveman and Ole Vahlgren. The company is owned by SEIER CAPITAL A/S, ANDRÉ ROGACZEWSKI HOLDING II ApS and SPSheikh Holding ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK -5,780,568 and a net result of DKK -21,221,120 compared with DKK -15,189,850 the year before. Equity in the 2025 report amounted to DKK -8,126,690.